[Prostatic carcinoma: metabolic effect of percutaneous beta-estradiol (author's transl)]

Nouv Presse Med. 1979 Nov 26;8(46):3801-2.
[Article in French]

Abstract

Twenty one patients suffering from carcinoma of the prostate, confirmed histologically and previously untreated, received treatment in the form of 17 beta-estradiol administered percutaneously. At a dose of 6 mg of estradiol per day, testosterone levels fell to a mean of 1 ng/ml. No change in lipids, lipoproteins nor cholinesterase were detected.

Publication types

  • English Abstract

MeSH terms

  • Administration, Topical
  • Estradiol / administration & dosage
  • Estradiol / therapeutic use*
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Testosterone / blood

Substances

  • Testosterone
  • Estradiol